www.hivandhepatitis.com

Skip to content

Back HIV Prevention

CROI 2017: A Combination of Factors Has Reduced HIV Infections in Hard-Hit Part of Africa

Details: Category: HIV/AIDS Epidemiology & Mortality; Published on Wednesday, 15 February 2017 00:00; Written by Gus Cairns

HIV incidence has started to tumble in the Rakai cohort, one of the best-studied groups of people in Africa, according to a report at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. The annual HIV infection rate has fallen 40% in the last 4 years, researchers said. A combination of factors -- including wider availability of antiretroviral therapy, increased male circumcision, and later age of sexual debut in young people -- all appear to be contributing to this decline.

alt

CROI 2017: Treatment or Watchful Waiting for Cervical Abnormalities in Women with HIV?

Details: Category: HIV-Related Conditions; Published on Wednesday, 15 February 2017 00:00; Written by Carole Leach-Lemens

Close monitoring of earlier-stage cervical abnormalities (CIN-2) may be preferable to treatment for many women with HIV, a U.S. study suggests. The findings, presented at the Conference on Retroviruses and Opportunistic Infections this week in Seattle, show that CIN-2 regressed in over three-quarters of women taking antiretroviral therapy, without the need for CIN treatment. A higher CD4 count was associated with a lower likelihood that lesions would progress.

alt

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

Details: Category: HIV Prevention; Published on Tuesday, 27 December 2016 00:00; Written by Gus Cairns

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment

Details: Category: Experimental HIV Drugs; Published on Tuesday, 14 February 2017 00:00; Written by Liz Highleyman

Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a Phase 2 clinical trial, according to study results presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle and published online in The Lancet HIV.

alt

First Large Study of Long-Acting Injectable for HIV Prevention Now Underway

Details: Category: Pre-exposure Prophylaxis (PrEP); Published on Tuesday, 27 December 2016 00:00; Written by HIVandHepatitis.com

The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.

alt

CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch

Details: Category: HIV Treatment; Published on Tuesday, 14 February 2017 00:00; Written by Liz Highleyman

People who switched from standard antiretroviral therapy to a 2-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load for 48 weeks in a pair of late-stage clinical trials, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

1. HIV Undetectable = Uninfectious

Details: Category: Treatment as Prevention; Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

Evidence continues to accumulate showing that HIV-positive people on effective combination antiretroviral therapy (ART) with a consistently undetectable viral load have a very low -- perhaps as low as zero -- risk of transmitting the virus.

alt

Golden Compass Program Launches at San Francisco General Hospital

Details: Category: HIV & Aging; Published on Tuesday, 07 February 2017 00:00; Written by Liz Highleyman

The Golden Compass program is now open at Zuckerberg San Francisco General Hospital's Ward 86, offering one-stop shopping for HIV-positive people age 50 and older. The program, which started seeing patients this past fall, held its official launch party on February 3.

alt

2. Quicker, Simpler, and Better Antiretroviral Therapy

Details: Category: HIV Treatment; Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

Modern antiretroviral therapy (ART) is highly effective and well-tolerated, but researchers continue to refine, streamline, and optimize treatment strategies. Studies presented this year show the benefits of starting ART as soon as possible after HIV diagnosis and suggest that fewer drugs taken less often may be effective for many people.

alt

Hope Overshadowed -- The National HIV PrEP Summit

Details: Category: Pre-exposure Prophylaxis (PrEP); Published on Tuesday, 31 January 2017 00:00; Written by Gus Cairns

The U.S. National HIV PrEP Summit, which took place in early December in San Francisco, was designed as an event of celebration and hope. Its structure, its speakers, even the way the plenary room was designed and the way the speakers dressed, all conveyed one message: we are all in this together, and pre-exposure prophylaxis (PrEP) really is the game-changer we have been looking for.

alt

3. Renewed Focus on HIV Vaccines and Antibodies

Details: Category: Search for a Cure; Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

Researchers intensified the search for novel types of therapies to prevent, treat, and potentially cure HIV, including immune-based strategies such as antibodies and vaccines.

alt

No New HIV Infections in Northern California Kaiser PrEP Program, but STI Rates Rising

Details: Category: Pre-exposure Prophylaxis (PrEP); Published on Tuesday, 24 January 2017 00:00; Written by Liz Highleyman

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a report in the December 15, 2016, Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of chlamydia and gonorrhea is high, suggesting that sexually transmitted infection (STI) testing may be needed quarterly rather than every 6 months.

alt

4. PrEP Use Widens, But Disparities Remain

Details: Category: Pre-exposure Prophylaxis (PrEP); Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

Pre-exposure prophylaxis (PrEP) was again a major HIV story in 2016. The latest figures from a pharmacy survey by Gilead Sciences showed that more than 79,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for HIV prevention, but the survey does not include all PrEP providers and most experts think this estimate is low.

alt

Study Shows Supervised Injection Facility Would Be Cost-Effective in San Francisco

Details: Category: People Who Inject Drugs; Published on Tuesday, 17 January 2017 00:00; Written by Liz Highleyman

Establishing a supervised consumption facility for people who inject drugs in San Francisco could reduce new HIV and hepatitis C virus (HCV) infections, decrease overdose deaths, and save millions of dollars, according to a mathematical modeling study recently published online in the Journal of Drug Issues.

alt

5. HIV Prevention for Women

Details: Category: HIV Sexual Transmission; Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

Use of Truvada for pre-exposure prophylaxis (PrEP) is highly effective and is now widely used among gay men, but biomedical HIV prevention for women has lagged behind.

alt

HIVandHepatitis.com 2016 Conference Coverage

Details: Category: HIV Treatment; Published on Thursday, 29 December 2016 00:00; Written by HIVandHepatitis.com

Article listings by topic for HIVandHepatitis.com conference coverage in 2016, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, International AIDS Conference, and AASLD Liver Meeting.

alt

6. HIV Incidence Falls, But Not for Young Black Gay Men

Details: Category: HIV/AIDS Epidemiology & Mortality; Published on Thursday, 22 December 2016 00:00; Written by HIVandHepatitis.com

New data show that while new HIV infections and diagnoses have decreased overall, they remain high for some population groups -- especially young black gay men in the U.S.

Top 10 HIV and Hepatitis Stories of 2016

Details: Category: HIV Treatment; Published on Wednesday, 28 December 2016 00:00; Written by HIVandHepatitis.com

Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.

alt

UCSF/amfAR HIV Cure Summit Reviews Progress in Cure-Related Research

Details: Category: Search for a Cure; Published on Wednesday, 21 December 2016 00:00; Written by Liz Highleyman

Researchers at the amfAR Institute for HIV Cure Research at the University of California at San Francisco (UCSF) presented an update on their latest cure-related work at a World AIDS Day summit on December 1. This multidisciplinary effort aims to understand HIV reservoirs within the body and ultimately to control or eliminate the virus. alt

Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies

Details: Category: HIV Treatment; Published on Tuesday, 27 December 2016 00:00; Written by Liz Highleyman

Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.

alt

IDWeek 2016: Comorbidities Are Common and Rising Among People with HIV

Details: Category: HIV-Related Conditions; Published on Thursday, 15 December 2016 00:00; Written by Liz Highleyman

People living with HIV are increasingly experiencing a range of non-AIDS-related comorbidities as the population ages, including cardiovascular disease, kidney impairment, and bone loss leading to fractures, according to research presented at the recent IDWeek 2016 meeting in New Orleans.

alt

Subcategories

Page 6 of 101